heptapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Free acid form of the heptapeptide; depends on terminal groups |
| Molecular mass | About 813.9 g/mol | Average mass used for mass spectrometry confirmation |
| Appearance | White to off-white solid | Supplied as a lyophilised powder; hygroscopic |
| Solubility class | Freely soluble in aqueous media | Water, saline, and phosphate buffers; limited organic solubility |
| Typical storage temperature | -20 degrees Celsius | Long term and dry; short working periods may use 2 to 8 degrees Celsius |
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Identity and purity of semax are established with reversed-phase high-performance liquid chromatography coupled to ultraviolet detection, usually at 214 nanometres. Mass spectrometry, most often electrospray ionisation in positive mode, confirms the molecular mass and reveals truncated sequences. Amino acid analysis and peptide mapping after enzymatic digestion provide additional structural confirmation. Laboratories typically report purity as the percentage area of the main peak, a figure that does not capture isomeric or oxidised variants unless the method resolves them.
The peptide is prone to several degradation pathways. Oxidation of the methionine residue produces a sulfoxide that elutes close to the parent peak in many chromatographic systems. Hydrolysis of peptide bonds and deamidation of susceptible residues in related sequences also reduce purity over time. Lyophilised material kept dry at minus twenty degrees Celsius and shielded from light is the most stable form commonly described in laboratory practice.
The C-terminal Pro-Gly-Pro extension is not incidental. Proline-rich tails are known to resist several common peptidases, and the published literature attributes the longer half-life of Semax, relative to unmodified ACTH fragments, to this feature. The modification also removes the melanocyte-stimulating and corticosteroidogenic activity that characterizes longer ACTH-derived sequences. Because the molecule is small and hydrophilic, it is typically formulated as an aqueous solution for intranasal or parenteral delivery. Acetylation or amidation at the termini appears in closely related research peptides and shifts the mass by a fixed increment.
Reported pharmacological work centers on neurotrophic signaling, including changes in BDNF and NGF expression in hippocampal tissue in animal models. Human data come largely from studies conducted in Russia, and how well those results generalize to other populations remains an open question. Regulatory status differs sharply by jurisdiction: Semax is a registered prescription medicine in Russia, while it holds no approved marketing status in the United States or the European Union. Outside such jurisdictions it is generally handled as a research chemical, which affects both documentation and quality expectations.
=== Fluctuating salinity: dilute and dry-down === Harold Blum noted in 1957 that if proto-nucleic acid chains spontaneously form duplex structures, then there is no way to dissociate them. The Oparin-Haldane hypothesis addresses the formation, but not the dissociation, of nucleic acid polymers and duplexes. However, nucleic acids are unusual because, in the absence of counterions (low salt) to neutralize the high charges on opposing phosphate groups, the nucleic acid duplex dissociates into single chains. Early tides, driven by a close moon, could have generated rapid cycles of dilution (high tide, low salt) and concentration (dry-down at low tide, high salt) that exclusively promoted the replication of nucleic acids through a process dubbed tidal chain reaction (TCR). This theory has been criticized on the grounds that early tides may not have been so rapid, although regression from current values requires an Earth–Moon juxtaposition at around two Ga, for which there is no evidence, and early tides may have been approximately every seven hours. Another critique is that only 2–3% of the Earth's crust may have been exposed above the sea until late in terrestrial evolution.
{\displaystyle {\begin{aligned}u_{x}&={\frac {4{\sqrt {2}}}{3{\sqrt {3}}}}\,U_{0}\left[\,\sin \left(kx-{\frac {\pi }{3}}\right)\cos \left(ky+{\frac {\pi }{3}}\right)\sin \left(kz+{\frac {\pi }{2}}\right)-\cos \left(kz-{\frac {\pi }{3}}\right)\sin \left(kx+{\frac {\pi }{3}}\right)\sin \left(ky+{\frac {\pi }{2}}\right)\,\right]e^{-3\nu k^{2}t}\\u_{y}&={\frac {4{\sqrt {2}}}{3{\sqrt {3}}}}\,U_{0}\left[\,\sin \left(ky-{\frac {\pi }{3}}\right)\cos \left(kz+{\frac {\pi }{3}}\right)\sin \left(kx+{\frac {\pi }{2}}\right)-\cos \left(kx-{\frac {\pi }{3}}\right)\sin \left(ky+{\frac {\pi }{3}}\right)\sin \left(kz+{\frac {\pi }{2}}\right)\,\right]e^{-3\nu k^{2}t}\\u_{z}&={\frac {4{\sqrt {2}}}{3{\sqrt {3}}}}\,U_{0}\left[\,\sin \left(kz-{\frac {\pi }{3}}\right)\cos \left(kx+{\frac {\pi }{3}}\right)\sin \left(ky+{\frac {\pi }{2}}\right)-\cos \left(ky-{\frac {\pi }{3}}\right)\sin \left(kz+{\frac {\pi }{3}}\right)\sin \left(kx+{\frac {\pi }{2}}\right)\,\right]e^{-3\nu k^{2}t}\end{aligned}}}
It was most popular in the 17th century, but was discontinued in the early 19th century when its composition became generally known to artists who replaced the said pigment by a totally different blend -but keeping the original name, mummia or mummy brown-yielding a similar tint and based on ground minerals (oxides and fired earths) and or blends of powdered gums and oleoresins (such as myrrh and frankincense) as well as ground bitumen. These blends appeared on the market as forgeries of powdered mummy pigment but were ultimately considered as acceptable replacements, once antique mummies were no longer permitted to be destroyed. In 1890, about 180,000 mummified cats were excavated and shipped from Egypt to England to be processed for use in fertilizer.
Sources: en.wikipedia.org
=== Reduction of endogenous quinones === NQO1 plays a role in ubiquinone and vitamin E quinone metabolism. These quinones protect cellular membranes from peroxidative injury in their reduced state. Furthermore, reduced forms of ubiquinone and vitamin E quinone have been shown to possess antioxidant properties that are superior to their non-reduced forms.
=== Analogues === Analogues of ETH-LAD include nor-LSD, LSD, PRO-LAD, IP-LAD, AL-LAD, FLUORETH-LAD, and CE-LAD, among others. 1P-ETH-LAD, a prodrug of ETH-LAD, has been developed and encountered as a novel designer drug.
GLaDOS (Genetic Lifeform and Disk Operating System) is a rampant artificial intelligence computer system that controls Aperture Laboratories, and is the primary antagonist for the Portal series. She is voiced by Ellen McLain. She awakens the player-character Chell in the first game, tasking her through the dangerous testing course, but Chell manages to escape and appears to destroy her, though later revealed to have had her personality stored within a black box. Within the second game, Wheatley accidentally reawakens GLaDOS, and eventually convinces Chell to initiate a core transfer to replace her with himself. GLaDOS, placed into a module powered by a potato battery, is forced to work with Chell to depose Wheatley from power before the Aperture facility is destroyed. While exploring the older sections of the facility with GLaDOS's potato battery form (known informally as "PotatOS" by fans), it is revealed that her consciousness is based, at least in part, on an uploaded version of Cave Johnson's assistant, Caroline. Caroline was unwilling to be uploaded to a computer, but was forced to do so by Cave. This potentially contributed to GLaDOS's homicidal tendencies, alongside the mental adjustments and tweaking performed by the scientists working on her. In the tie-in comic Portal 2: Lab Rat, it is revealed that the personality cores, such as Wheatley, were attached to GLaDOS in an attempt to manage and control her by acting as an artificial "conscience." Discussing the morality core, scientist Doug Rattmann quips, "You can always ignore your conscience."
Sources: en.wikipedia.org
Militias from the Cao Đài sect, which had initially joined the Viet Minh in their struggle against the return of the French, made a truce with France when their leader was captured on 6 June 1946. The Viet Minh later attacked the Cao Đài after open conflict had erupted with France, which led them to join the French side. The Viet Minh assassinated the Hòa Hảo leader Huỳnh Phú Sổ in April 1947. Vietnamese society also polarized along ethnic lines: the Nùng and Chinese Nùng minority assisted the French, while the Tày assisted the Việt Minh. The Khmer Krom also sided with France. Surviving Vietnamese nationalist partisans and politico-religious groups rallied behind the exiled Bảo Đại to reopen negotiations with France in opposition to communist domination. The State of Vietnam (SVN), with Bảo Đại as Chief of State, was established and positioned within the anticommunist Western Bloc. With the recognition of the DRV by China and the Soviet Union, and the recognition of the SVN by the United States in 1950, the civil war and the colonial war in Vietnam became internationalized and intertwined with the global Cold War.
Proteins can be engineered to improve the chance of successful protein crystallization. A common way is by trimming the recombinant construct to remove N- and C- terminal parts, which are frequently disordered or poorly structured ("high entropy"). Surface entropy reduction entails replacing surface residue clusters with high conformational entropy (usually lysine, glutamate, and glutamine) with alanines. In a similar vein, replacing lysine with arginine in bulk has proven useful. It is also possible to engineer in crystal contacts by mutating residues. An even more advanced method involves the use of "chaperone" proteins known to be more crystallizable. This can be achieved by designing a fusion protein consisting of the protein with unknown structure and a protein domain known to crystalize well. The interaction in question can also be intermolecular, for example between the candidate protein and some antibody Fab fragments selected to bind tightly to the protein, or between a candidate-maltose-binding protein (MBP) fusion and a protein specifically designed to bind MBP. Many methods for protein engineering require some forward knowledge of protein structure, either simply knowing what residues are surface or buried or knowing the full tertiary structure. Modern protein structure prediction tools are largely sufficient. It is also possible to predict the result of crystallization using these methods. Cystine residues on the surface tend to cause trouble for recombinant protein production by causing aggregation. They can be replaced with alanines.
Contamination has also been seen in water wells and other sources of drinking water. This contamination is seen in US, United Kingdom, Germany, Japan, and Canada, but information from most developing countries is nearly nonexistent. The lack of information on PFAS contamination in developing countries, especially those in Africa, are due to structural socioeconomic inequality and lack of access to the expensive laboratory capabilities required for PFAS quantification.
Sources: en.wikipedia.org
It is described as a synthetic analogue of the ACTH(4–10) fragment, a short segment of adrenocorticotropic hormone. Its sequence differs from that fragment and includes two proline residues, which influence stability and behaviour in solution.
It appears in Russian pharmaceutical listings as a nasal formulation, but it is not an authorised medicine in the United States or the European Union. Outside those markets it is normally encountered as a research chemical rather than a prescription product.
Laboratory and animal work points to melanocortin signalling and changes in neurotrophic factor levels, especially brain-derived neurotrophic factor. The exact receptor targets and the degree to which these findings transfer to humans are still unresolved.
The main proposal is modulation of neurotrophic factors such as brain-derived neurotrophic factor, supported largely by animal experiments. Receptor-level targets have not been firmly established. Most reviews describe the mechanism as only partially characterized.